Osyka Corporation (OSKA PINK) stock market data APIs
$0.1179
0(0%)
as of August 25, 2025
Try our APIs with
free plan!
Osyka Corporation Financial Data Overview
Price chart is built with
Anychart
Osyka Corporation, an oil and gas company, engages in the acquisition, development, exploration, and production of oil and gas properties in Mississippi and Texas. The company was founded in 1990 and is based in Houston, Texas. Osyka Corporation is former subsidiary of Legado Resources LLC and Tellus Energy Group, LLC.
Prev. Close
0.1179
Open
0.1179
High
0.1179
Low
0.1179
52 wk Range
0.0026-2.5
Market Cap
483 M
Shares Outstanding
439 M
Revenue
1 519 K
EPS
-0.0003
Beta
-2.102
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Osyka Corporation data using free add-ons & libraries
Get Osyka Corporation Fundamental Data
Osyka Corporation Fundamental data includes:
- Net Revenue: 1 519 K
- EBITDA: -2 079 054
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Osyka Corporation News
New
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Press Release 27 January 2021 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB (publ; IMMU.ST) announced today that its in...
Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS)
Press Release 26 January 2021 Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS) Immunicum AB (publ; IMMU.ST) announced today that ...
Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021
Press Release 22 January 2021 Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 At the Extraordinary General Meeting (the “EGM”) of Immunicum AB (publ) (IM...
Immunicum AB (publ) Announces Transitions in Board of Directors
Press Release 21 January 2021 Immunicum AB (publ) Announces Transitions in Board of Directors Immunicum AB (publ: IMMU.ST) today announced that Michael Oredsson has decided to resign his position a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
